Tekla Life Sciences Investors (NYSE:HQL) Short Interest Update

Tekla Life Sciences Investors (NYSE:HQL) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 17,500 shares, a decline of 61.8% from the September 15th total of 45,800 shares. Based on an average daily trading volume, of 68,700 shares, the short-interest ratio is presently 0.3 days.

NYSE:HQL traded up $0.26 during trading hours on Thursday, hitting $20.73. The stock had a trading volume of 306 shares, compared to its average volume of 77,357. The company has a 50 day simple moving average of $21.46 and a two-hundred day simple moving average of $20.74. Tekla Life Sciences Investors has a one year low of $16.60 and a one year high of $22.70.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 30th. Shareholders of record on Friday, August 27th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 8.30%. This is an increase from Tekla Life Sciences Investors’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend was Thursday, August 26th.

In other Tekla Life Sciences Investors news, President Daniel R. Omstead acquired 6,403 shares of Tekla Life Sciences Investors stock in a transaction that occurred on Wednesday, August 11th. The stock was acquired at an average cost of $21.63 per share, for a total transaction of $138,496.89. Following the purchase, the president now owns 146,489 shares of the company’s stock, valued at $3,168,557.07. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.06% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in HQL. UBS Group AG boosted its holdings in Tekla Life Sciences Investors by 16.0% in the 1st quarter. UBS Group AG now owns 121,568 shares of the company’s stock valued at $2,396,000 after purchasing an additional 16,784 shares during the period. Citigroup Inc. lifted its holdings in shares of Tekla Life Sciences Investors by 16.6% during the 1st quarter. Citigroup Inc. now owns 37,483 shares of the company’s stock worth $739,000 after acquiring an additional 5,337 shares during the last quarter. Barclays PLC bought a new stake in shares of Tekla Life Sciences Investors during the 1st quarter worth $35,000. Bessemer Group Inc. lifted its holdings in shares of Tekla Life Sciences Investors by 13.8% during the 1st quarter. Bessemer Group Inc. now owns 7,730 shares of the company’s stock worth $152,000 after acquiring an additional 937 shares during the last quarter. Finally, Stephens Inc. AR lifted its holdings in shares of Tekla Life Sciences Investors by 5.8% during the 1st quarter. Stephens Inc. AR now owns 16,561 shares of the company’s stock worth $326,000 after acquiring an additional 913 shares during the last quarter. 17.09% of the stock is owned by hedge funds and other institutional investors.

About Tekla Life Sciences Investors

Tekla Life Sciences Investors operates as a closed-end investment fund or Investment trust. The firm engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services.

Further Reading: Earnings Reports

Receive News & Ratings for Tekla Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekla Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.